Compare AFCG & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AFCG | COEP |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.8M | 91.2M |
| IPO Year | 2020 | N/A |
| Metric | AFCG | COEP |
|---|---|---|
| Price | $3.48 | $16.40 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 359.9K | 92.3K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 6.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $24,563,601.00 | N/A |
| Revenue This Year | $1,334.03 | N/A |
| Revenue Next Year | $17.33 | N/A |
| P/E Ratio | $7.47 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.06 | $6.80 |
| 52 Week High | $5.78 | $21.41 |
| Indicator | AFCG | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 54.06 | 72.18 |
| Support Level | $3.44 | $13.77 |
| Resistance Level | $3.84 | $19.19 |
| Average True Range (ATR) | 0.19 | 1.15 |
| MACD | -0.02 | 0.47 |
| Stochastic Oscillator | 54.32 | 87.62 |
Advanced Flower Capital Inc is an externally managed Maryland corporation that operates as a Business Development Company (BDC). The firm's primary operations involve originating, structuring, underwriting, and managing senior secured loans and other debt securities. Its investment portfolio includes loans to state law-compliant cannabis operators, ancillary cannabis businesses, and middle-market companies in other industries. These loans are typically secured by collateral such as real estate, equipment, cash flows, and license values.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical and technology company. The biopharmaceutical division focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its research and development efforts. The technology division focuses on enhancing operational capabilities through technologies. This division features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency. It derives the majority of the revenue from the Technology segment.